Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors

Rhea-AI Summary

Femasys (NASDAQ: FEMY) appointed Dr. Kenneth D. Eichenbaum to its board on March 18, 2026. Dr. Eichenbaum is a board-certified anesthesiologist with over 20 years evaluating biotech and medical device companies, and holds degrees from Icahn School of Medicine, University of Pennsylvania, and Wharton.

The company thanked Joshua Silverman for his board service and highlighted Dr. Eichenbaum’s clinical, engineering, and finance expertise as strategic support for Femasys’ growth in women’s reproductive health.

Positive

• Board expertise: adds clinical, engineering, and finance experience
• Industry experience: 20+ years evaluating biotech and device companies

Negative

• Board turnover: departure of Joshua Silverman removes a capital markets perspective

News Market Reaction – FEMY

+3.45%

1 alert

+3.45% News Effect

+$1M Valuation Impact

$35M Market Cap

0.0x Rel. Volume

On the day this news was published, FEMY gained 3.45%, reflecting a moderate positive market reaction. This price movement added approximately $1M to the company's valuation, bringing the market cap to $35M at that time.

Data tracked by StockTitan Argus on the day of publication.

ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the appointment of Kenneth D. Eichenbaum, M.D., M.S.E., to its Board of Directors. Dr. Eichenbaum is a board-certified anesthesiologist with clinical affiliations at Corewell Health William Beaumont University Hospital and Trinity Health Oakland Hospital, bringing deep clinical expertise and strategic insight developed through more than 20 years of evaluating biotechnology and medical device companies and advising investment firms. He completed a fellowship at Stanford University Medical Center and earned his M.D. from the Icahn School of Medicine at Mount Sinai, with additional degrees in engineering from the University of Pennsylvania and in finance from The Wharton School.

“As we continue advancing innovative solutions in women’s health, Dr. Eichenbaum brings a unique combination of clinical and technical expertise, along with deep financial insight, that will be invaluable to Femasys,” said Kathy Lee-Sepsick, Founder and Chief Executive Officer of Femasys. “His experience evaluating and advising biotechnology and medical device companies adds an important strategic perspective to our Board, and we are thrilled to welcome him at this important stage in the Company’s growth.”

Dr. Eichenbaum commented, “Femasys is advancing innovative, non-surgical solutions designed to improve the patient experience while reducing cost and complexity in women’s reproductive care. I look forward to working with the Board and management team to support the Company’s continued growth and innovation.”

The Company also expresses its appreciation to Joshua Silverman for his service on the Board of Directors. His capital markets perspective and strategic counsel supported Femasys during a period of important growth and development.

About Femasys
Femasys is a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide through its broad, patent-protected portfolio of novel, in-office therapeutic and diagnostic products. As a U.S. manufacturer with global regulatory approvals, Femasys is actively commercializing its lead product innovations in the U.S. and key international markets. Femasys’ fertility portfolio includes FemaSeed^® Intratubal Insemination (ITI), a groundbreaking first-step infertility treatment; FemSperm^®, a CLIA waived sperm preparation and analysis product line; and FemVue^®, a companion diagnostic for fallopian tube assessment. Published clinical trial data demonstrate that FemaSeed achieved more than double the pregnancy rates of traditional IUI, with a comparable safety profile and high patient and practitioner satisfaction.¹

FemBloc^® permanent birth control is the first and only non-surgical, in-office alternative to centuries-old surgical sterilization that received full regulatory approval in Europe in June 2025, the UK in August 2025, and New Zealand in September 2025. Commercialization of this highly cost-effective, convenient and significantly safer approach will be completed through strategic partnerships in select European countries. Alongside FemBloc, the FemChec^®, diagnostic product provides an ultrasound-based test to confirm procedural success. Published data from initial clinical trials demonstrated compelling effectiveness, five-year safety, and high patient and practitioner satisfaction.² For U.S. FDA approval, enrollment in the FINALE pivotal trial (NCT05977751) is on-going.

Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.

References
¹Liu, J. H., Glassner, M., Gracia, C. R., Johnstone, E. B., Schnell, V. L., Thomas, M. A., L. Morrison, Lee-Sepsick, K. (2024). FemaSeed Directional Intratubal Artificial Insemination for Couples with Male-Factor or Unexplained Infertility Associated with Low Male Sperm Count. J Gynecol Reprod Med, 8(2), 01-12. doi: 10.33140/JGRM.08.02.08.

²Liu, J. H., Blumenthal, P. D., Castaño, P. M., Chudnoff, S. C., Gawron, L. M., Johnstone, E. B., Lee-Sepsick, K. (2025). FemBloc Non-Surgical Permanent Contraception for Occlusion of the Fallopian Tubes. J Gynecol Reprod Med, 9(1), 01-12. doi: 10.33140/JGRM.09.01.05.

Forward-Looking Statements 
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to obtain regulatory approvals for our FemBloc product candidate; develop and advance our current FemBloc product candidate and successfully enroll and complete the clinical trial; the ability of our clinical trial to demonstrate safety and effectiveness of our product candidate and other positive results; estimates regarding the total addressable market for our products and product candidate; our ability to commercialize our products and product candidate, our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.

Contacts: 
David Gutierrez, Dresner Corporate Services, (312) 780-7204, dgutierrez@dresnerco.com
Nathan Abler, Dresner Corporate Services, (714) 742-4180, nabler@dresnerco.com

FAQ

Who is Kenneth D. Eichenbaum and why did Femasys (FEMY) appoint him to the board on March 18, 2026?

Dr. Eichenbaum is a board-certified anesthesiologist with clinical and advisory experience in biotech and devices. According to the company, he brings clinical, engineering, and finance expertise to support Femasys’ strategic growth in women’s reproductive health.

What qualifications does new Femasys board member Dr. Kenneth D. Eichenbaum (FEMY) hold?

He holds an M.D., completed a Stanford fellowship, and has engineering and finance degrees. According to the company, his background includes clinical affiliations and over 20 years evaluating biotech and medical device companies.

How might Dr. Eichenbaum’s appointment affect Femasys (FEMY) strategy in women’s health?

His clinical and technical background may strengthen product evaluation and commercialization decisions. According to the company, his combined clinical, engineering, and financial insight will provide strategic perspective during the company’s growth phase.

Did Femasys (FEMY) announce any board departures alongside the March 18, 2026 appointment?

Yes, the company expressed appreciation for Joshua Silverman’s service on the board. According to the company, Silverman contributed capital markets perspective and strategic counsel during a period of important growth.

What clinical affiliations does Dr. Kenneth D. Eichenbaum have as noted by Femasys (FEMY)?

He has clinical affiliations at Corewell Health William Beaumont University Hospital and Trinity Health Oakland Hospital. According to the company, these affiliations underpin his practical clinical experience relevant to the company’s work.

Will Dr. Eichenbaum’s appointment to Femasys (FEMY) likely impact investor relations or capital strategy?

His finance and advisory background could enhance investor communications and strategic financing discussions. According to the company, his deep financial insight complements the board’s experience amid the company’s growth stage.